BACKGROUND: There is evidence that iron may play a role in the pathology of Alzheimer's disease (AD). There may be genetic factors that contribute to iron deposition resulting in tissue damage thus exacerbating AD. METHODS: We have genotyped 269 healthy elderly controls, 191 cases with definite or probable AD, and 69 with mild cognitive impairment (MCI) from the OPTIMA cohort. RESULTS: We have examined the interaction between the C2 variant of the transferrin (TF) gene and the C282Y allele of the haemochromatosis (HFE) gene as risk factors for developing AD. Our results showed that each of the two variants was associated with an increased risk of AD only in the presence of the other. Neither allele alone had any effect. Carriers of both variants were at 5 times greater risk of AD compared with all others. The interaction was significant by logistic regression (p = 0.014) and by synergy factor analysis (p = 0.015, synergy factor = 5.1). Further, carriers of these two alleles plus apolipoprotein E epsilon4 (APOE4) were at still higher risk of AD: of the 14 tri-carriers of the three variants, identified in this study, 12 had AD and two MCI. CONCLUSION: We suggest that the combination of TF C2 and HFE C282Y may lead to an excess of redox-active iron and the induction of oxidative stress in neurones, which is exacerbated in carriers of APOE4. Since 4% of Northern Europeans carry the two iron-related variants and since iron overload is a treatable condition, these results merit replication.
BACKGROUND: There is evidence that iron may play a role in the pathology of Alzheimer's disease (AD). There may be genetic factors that contribute to iron deposition resulting in tissue damage thus exacerbating AD. METHODS: We have genotyped 269 healthy elderly controls, 191 cases with definite or probable AD, and 69 with mild cognitive impairment (MCI) from the OPTIMA cohort. RESULTS: We have examined the interaction between the C2 variant of the transferrin (TF) gene and the C282Y allele of the haemochromatosis (HFE) gene as risk factors for developing AD. Our results showed that each of the two variants was associated with an increased risk of AD only in the presence of the other. Neither allele alone had any effect. Carriers of both variants were at 5 times greater risk of AD compared with all others. The interaction was significant by logistic regression (p = 0.014) and by synergy factor analysis (p = 0.015, synergy factor = 5.1). Further, carriers of these two alleles plus apolipoprotein E epsilon4 (APOE4) were at still higher risk of AD: of the 14 tri-carriers of the three variants, identified in this study, 12 had AD and two MCI. CONCLUSION: We suggest that the combination of TF C2 and HFEC282Y may lead to an excess of redox-active iron and the induction of oxidative stress in neurones, which is exacerbated in carriers of APOE4. Since 4% of Northern Europeans carry the two iron-related variants and since iron overload is a treatable condition, these results merit replication.
Authors: Joseph F Pulliam; C Darrell Jennings; Richard J Kryscio; Daron G Davis; Dianne Wilson; Thomas J Montine; Frederick A Schmitt; William R Markesbery Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2003-05-15 Impact factor: 3.568
Authors: George Perry; Marta A Taddeo; Robert B Petersen; Rudy J Castellani; Peggy L R Harris; Sandra L Siedlak; Adam D Cash; Quan Liu; Akohiko Nunomura; Craig S Atwood; Mark A Smith Journal: Biometals Date: 2003-03 Impact factor: 2.949
Authors: Pradyumna D Phatak; Daniel H Ryan; Joseph Cappuccio; David Oakes; Caroline Braggins; Kim Provenzano; Shirley Eberly; Ronald L Sham Journal: Blood Cells Mol Dis Date: 2002 Jul-Aug Impact factor: 3.039
Authors: A T Merryweather-Clarke; M Worwood; L Parkinson; C Mattock; J J Pointon; J D Shearman; K J Robson Journal: Br J Haematol Date: 1998-05 Impact factor: 6.998
Authors: Omer T Njajou; Jeanine J Houwing-Duistermaat; Richard H Osborne; Norbert Vaessen; Jeanette Vergeer; Jan Heeringa; Huibert A P Pols; Albert Hofman; Cornelia M van Duijn Journal: Eur J Hum Genet Date: 2003-03 Impact factor: 4.246
Authors: Onofre Combarros; Marisa García-Román; Ana Fontalba; José L Fernández-Luna; Javier Llorca; Jon Infante; José Berciano Journal: Dement Geriatr Cogn Disord Date: 2003 Impact factor: 2.959
Authors: M J Burt; P M George; J D Upton; J A Collett; C M Frampton; T M Chapman; T A Walmsley; B A Chapman Journal: Gut Date: 1998-12 Impact factor: 23.059
Authors: J S K Kauwe; S Bertelsen; K Mayo; C Cruchaga; R Abraham; P Hollingworth; D Harold; M J Owen; J Williams; S Lovestone; J C Morris; A M Goate Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-06-05 Impact factor: 3.568
Authors: Keith D Coon; Andrew M Siegel; Stephanie J Yee; Travis L Dunckley; Claudius Mueller; Rashed M Nagra; Wallace W Tourtellotte; Eric M Reiman; Andreas Papassotiropoulos; Floyd F Petersen; Dietrich A Stephan; Wolff M Kirsch Journal: J Alzheimers Dis Date: 2006-08 Impact factor: 4.472
Authors: D J Lehmann; M Worwood; R Ellis; V L J Wimhurst; A T Merryweather-Clarke; D R Warden; A D Smith; K J H Robson Journal: J Med Genet Date: 2006-10 Impact factor: 6.318
Authors: David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki Journal: Hum Genet Date: 2013-07-03 Impact factor: 4.132
Authors: K J H Robson; A T Merryweather-Clarke; E Cadet; V Viprakasit; M G Zaahl; J J Pointon; D J Weatherall; J Rochette Journal: J Med Genet Date: 2004-10 Impact factor: 6.318
Authors: Ming D Li; Qing Xu; Xiang-Yang Lou; Thomas J Payne; Tianhua Niu; Jennie Z Ma Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-04-05 Impact factor: 3.568